Imagine a painful, itchy rash that thrives in the warm, moist folds of your skin—your armpits, groin, or under your breasts. That's inverse psoriasis, and it can be incredibly difficult to treat. Doctors recently tried a newer psoriasis medication, guselkumab, on a 48-year-old man with this condition. After three injections over 12 weeks, his skin lesions and the relentless itching showed marked improvement. This is a promising result for a single patient, offering a glimmer of hope where treatment options are often limited. However, it's crucial to remember this is just one case. We have no way of knowing if this drug would help another person with the same condition, and we don't have any information on side effects or how long the improvement might last. The finding is a starting point for asking new questions, not a proven solution.
Photo by Dmytro Vynohradov / Unsplash
Can a psoriasis drug help with a rare, hard-to-treat skin condition?
Plain Language Summary
What this means for you:
One patient improved, but it's too soon to know if this treatment works for others. What this means for you:
One patient improved, but it's too soon to know if this treatment works for others. View Original Abstract ↓
Inverse psoriasis is a special type of psoriasis whose pathogenesis is not yet fully understood, and for which there is no consensus guideline due to marked therapeutic challenges associated with the specific anatomic location of lesions. Immune-mediated inflammation plays a key role in its development, and the lesions are susceptible to friction and humidity, which makes the affected area less tolerant to treatment. In this article, we report a successful case of Inverse psoriasis treated with Guselkumab in a 48-years-old male, who was treated with three subcutaneous injections of Guselkumab and exhibited marked improvement in cutaneous lesions and pruritus at 12 weeks of treatment. A review of the relevant literature was also conducted with the aim of providing clinicians with more references for the treatment of this disease.